Q1 net loss $9.0M; cash $16.6M; Phase 2 vaping cessation data positive; Phase 3 ORCA-3 topline due Q2

ACHIEVE LIFE SCIENCES, INC.

2023-Q1 EPS reported -$0.50

Net loss of $9.0M for Q1 2023; cash, equivalents & restricted cash $16.6M as of March 31, 2023.
Phase 2 ORCA-V1 trial: cytisinicline 31.8% quit rate vs placebo 15.1%; 2.6x odds (p=0.035).
Phase 3 ORCA-3 trial (792 adults) fully enrolled; topline results expected Q2 2023.
Three new board members appointed: Stuart Duty, Thomas King, and Tom Sellig.
Shares outstanding: 18,040,760 as of May 9, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACHIEVE LIFE SCIENCES, INC. reported the first quarter ended March 31, 2023 results: net income $9.0 million.

Period: the first quarter ended March 31, 2023
Net income: $9.0 million
Result: reported results

Exact text from the filing

Total net loss for the first quarter ended March 31, 2023 was $9.0 million.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ACHIEVE LIFE SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-019679

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.